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Abstract
Neurexins (NRXNs) are presynaptic terminal proteins and candidate neurodevelopmental disorder susceptibility genes;
mutations presumably upset synaptic stabilization and function. However, analysis of human cortical tissue samples by
RNAseq and quantitative real-time PCR at 8–12 postconceptional weeks, prior to extensive synapse formation, showed
expression of all three NRXNs as well as several potential binding partners. However, the levels of expression were not
identical; NRXN1 increased with age and NRXN2 levels were consistently higher than for NRXN3. Immunohistochemistry for
each NRXN also revealed different expression patterns at this stage of development. NRXN1 and NRXN3 immunoreactivity
was generally strongest in the cortical plate and increased in the ventricular zone with age, but was weak in the
synaptogenic presubplate (pSP) and marginal zone. On the other hand, NRXN2 colocalized with synaptophysin in neurites of
the pSP, but especially with GAP43 and CASK in growing axons of the intermediate zone. Alternative splicing modifies the
role of NRXNs and we found evidence by RNAseq for exon skipping at splice site 4 and concomitant expression of KHDBRS
proteins which control this splicing. NRXN2 may play a part in early cortical synaptogenesis, but NRXNs could have diverse
roles in development including axon guidance, and intercellular communication between proliferating cells and/or
migrating neurons.
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Introduction
Neurodevelopmental conditions such as autism spectrum disor-
ders (ASDs) schizophrenia and intellectual disability are highly
heritable and can be regarded as disorders in formation of com-
plex neural circuitry which, although specified by genetic
instructions, relies on adaptive mechanisms to fine tune con-
nectivity. A large number of candidate susceptibility genes have
been identified (Pinto et al. 2010; Betancur 2011; Cukier et al.
2014; Kavanagh et al. 2015) many coding for proteins that inter-
act in synapse formation, stabilization and function, including
neurexins (NRXNs) as well as their postsynaptic binding part-
ners (Ye et al. 2010; Reichelt et al. 2012; Bang and Owczarek
2013) focusing attention on the synapse and aberrant circuitry
(Südhof 2008). However, synapses and their proteins are ubiqui-
tous in the brain, whereas circuit alterations identified post-
mortem, or by fMRI and EEG, suggest localized deficits in the
frontal and temporal lobes of the cerebral cortex in particular,
as well as in the cerebellum and basal ganglia (Courchesne et al.
2007; Miyata et al. 2009; Kubota et al. 2013; Catani et al. 2016).
Perhaps selected circuits are particularly sensitive to synaptic
dysfunction. Alternatively, uncovering susceptibility gene expre-
ssion patterns during early development may suggest additional
roles key to understanding these localized deficits.
The NRXN genes are among the largest in the genome, exceed-
ing 1Mb, and differentially spliced into thousands of isoforms
(Missler and Südhof 1998; Rowen et al. 2002; Schreiner et al. 2014).
Each NRXN gene codes for a longer α and shorter β transcript tran-
scribed from separate promoters (Ushkaryov et al. 1994). The
α transcript contains six laminin/NRXN/sex-hormone binding
globulin (LNS) domains and three epidermal growth factor (EGF)-
like domains while β transcripts have the same transmembrane
and cytoplasmic domain but only the sixth LNS domain (Ullrich
et al 1995; Missler and Südhof 1998). Six differential splicing sites
have been identified in α NRXNs (splice sites 1–6) two of which,
4 and 5, are also present in β NRXNs (Schreiner et al. 2014; see
Supplementary Fig. 1 ).
α NRXNs are involved in Ca2+-dependent neurotransmitter
release (Missler et al. 2003) their intracellular PDZ domain bind-
ing to proteins such as calcium/calmodulin-dependent serine
protein kinase (CASK) which couple NRXN-mediated cell adhe-
sion to synaptic vesicle exocytosis machinery (Hata et al. 1996).
However, they are not required for synapse formation (Missler
et al. 2003). β NRXNs also recruit other PDZ domain proteins to
the presynaptic membrane but chiefly bind to neuroligin (NLGN)
proteins across the synaptic cleft via their extracellular domain
(Ichtchenko et al. 1995; Koehnke et al. 2010) as do certain α
NRXN splice variants (Boucard et al. 2005; Reissner et al. 2013).
These events are regulated by alternative splicing of NRXN
genes (Ichtchenko et al. 1995; Ichtchenko et al. 1996). Different
roles in synaptogenesis and synaptic transmission have been
attributed to α and β NRXNs, due to separate ligand interactions
(Petrenko et al. 1996; Reissner et al. 2013).
Binding affinities differ between various pairs of NRXNs and
NLGNs, controlled by alternative splicing of both binding part-
ners (Comoletti et al. 2006). In vertebrates, NRXNs (and NLGNs)
are synthesized throughout the brain in all excitatory and
inhibitory neurons (Ichtchenko et al. 1995, 1996; Ullrich et al.
1995). The different α- and β NRXNs are coexpressed in the same
class of neuron (Ullrich et al. 1995); however, each type of NRXN
(1, 2, or 3; Ullrich et al. 1995) and also different α splice variants,
mRNA and protein (Schreiner et al. 2014; Schreiner et al. 2015)
are differentially distributed between different neuronal types.
In rodents, the STAR (Signal Transduction and Activation of
RNA) proteins KHDBRS1, 2, and 3 (also known as SAM68, SLM1,
and SLM2/T-STAR, respectively) regulate alternative splicing of
Nrxns (Iijima et al. 2011; Klein et al. 2013; Ehrmann et al. 2013)
and determine affinity for different binding partners (Vuong
et al. 2016).
Numerous studies have found deletions, truncations, and
copy number variants in NRXN genes at a higher frequency in
neurodevelopmental disorders than in the control groups. The
evidence is strongest for NRXN1. Two original studies detected
both NRXN1β gene variants (Feng et al. 2006) and α gene variants
(Friedman et al. 2006) in ASD patients. Subsequently multiple
studies have found evidence for NRXN1 as a candidate suscepti-
bility gene for ASD, schizophrenia and intellectual disability
(Szatmari et al. 2007; Kim et al. 2008; Kirov et al. 2008; Glessner
et al. 2009; Rujescu et al. 2009; Ching et al. 2010; Gauthier et al.
2011; Viñas Jornet et al. 2014). Mutations in NRXN2 and 3 have
also been implicated although the evidence is less compelling;
an identified NRXN2 gene mutation was found to result in a
truncated protein which did not bind its NLGN partner in vitro
(Gauthier et al. 2011) and there is supporting evidence from gen-
ome wide association studies (Cukier et al. 2014). NRXN3 muta-
tions have been detected in autistic children from four families
(Vaags et al. 2012) and a subsequent association study linked
NRXN3 polymorphisms with schizophrenia (Hu et al. 2013). In
mice knock-out of Nrxn1α-encoded isoforms targeting the first
coding exon resulted in a mild ASD-related phenotype (Etherton
et al. 2009; Grayton et al. 2013). Knock-out of Nrxn2 exon 23,
shared by α and β isoforms, resulted in deficits in social inter-
action, social memory and anxiety-like behavior (Dachtler et al.
2014; Born et al. 2015).
Preliminary studies suggest that NRXNs and associated
genes are all expressed at the earliest stages of cortical plate
(CP) formation (Ip et al. 2010; Kang et al. 2011) when very few
synapses are present in the human cerebral cortex (Kostovic´
and Rakic 1990). This suggests additional roles for NRXNs
although an alternative (but not mutually exclusive) explan-
ation would be that perhaps correct functioning of precocious
synaptic circuitry present in the presubplate (pSP) and marginal
zone (MZ) is crucial to cortical development. To explore these
possibilities further, we have studied the expression of the
three NRXN genes at these early stages and provided additional
information on the expression of NRXN binding partners, and
regulators of NRXN alternative splicing, to gain a more com-
plete picture of how mutations in NRXNs may perturb human
cortical development. Some of these findings have already
been published in abstract form (Harkin et al. 2015).
Methods and Materials
Human Tissue
Human fetal brain samples between 8 and 12 postconceptional
weeks (PCWs) were obtained from the MRC-Wellcome Trust
Human Developmental Biology Resource (HDBR, http://www.
hdbr.org; Gerrelli et al 2015). Brains were collected from termi-
nations of pregnancy with maternal written consent and
approval from the Newcastle and North Tyneside NHS Health
Authority Joint Ethics Committee. Age was determined by the
assessment of external morphology (O’Rahilly et al 1987; Bullen
and Wilson 1997) and by comparing foot and heel to knee
length to a standard growth chart (Hern 1984). Adult brain sec-
tions were obtained from the Newcastle Brain Tissue Resource
(NBTR). Brains were collected with written consent from donors
postmortem with approval from the Newcastle and North
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Tyneside NHS Health Authority Joint Ethics Committee. Both
the HDBR and NBTR are regulated by the UK Human Tissue
Authority (HTA; www.hta.gov.uk) and operate in accordance
with the relevant HTA Codes of Practice.
Whole fetal brains were isolated from the skull and the
meninges were removed. The hemispheres were split apart
allowing removal of the choroid plexus and subcortical struc-
tures leaving only the cerebral cortex. One or both hemi-
spheres were then divided into six sections. Each hemisphere
represented an independent sample. The temporal lobe,
including lateral and medial walls was removed and labeled
section 6. The remaining cortex was divided into five sections
of equal width from the anterior (A) to the posterior (P) pole of
the cortex including lateral and medial cortical walls (labeled
1–5). Sections 1, 3, 5, and 6 were used for RNA extraction and
corresponded to anterior, central (C), posterior and temporal
(T) regions (see Fig. 1). Sections were immediately frozen and
stored at –80°C and subsequently used to extract RNA. Other
fetal brains were fixed in buffered 4% paraformaldehyde solu-
tion (Sigma Aldrich, Dorset, UK) and embedded in paraffin
wax before sectioning.
RNA Extraction and Reverse Transcription
RNA was extracted from sections 1 (A), 3 (C), 5 (P), and 6 (T)
using the QIAgen RNeasy mini kit (Qiagen, Manchester, UK)
according to the manufacturer’s protocol. Sixty-three samples
were taken in all at 9, 11, and 12 PCW (see Table 1). The concen-
tration and quality of RNA was measured using the Nanodrop
8000 (Thermo Fisher Scientific, Cramlington, UK) to detect spec-
trophotometric absorbance at 260 nm. To control for RNA purity
and degradation, 260/230 and 260/280 spectrophotometric
ratios were only accepted between the ranges of 1.8 and 2.1. A
selection of the RNA was run on the Bioanalyser 2100 (Agilent,
Stockport, UK) and all RIN values measured were above 7.
To reverse transcribe the RNA to cDNA, 2 µg of random pri-
mers (Promega, Southhampton, UK), up to 5 µg of RNA, and 1 µl
dNTPs (10mM) were combined and the volume made up to 13 µl
using RNase free water. The mixture was heated at 65°C for
5min and cooled on ice for a minimum of 1min. Four microli-
ters 5× first strand buffer, 1 µL (200U/µL) Superscript Reverse
Transcriptase (Invitrogen, Thermo Fisher Scientific), 1 µL of 1M
dithiothreitol and 1 µL RNaseOut Recombinant Ribonuclease
Inhibitor (Invitrogen, 40U/µL) were added to the same tube and
incubated at 25°C for 5min before being heated to 50°C for
60min. The reaction was inactivated by heating to 70°C for
15min and the cDNA was stored at –20°C. Total cDNA concen-
tration was measured using the Nanodrop 8000 (Thermo Fisher
Scientific) to detect spectrophotometric absorbance at 260nm
and 260/230, 260/280 spectrophotometric ratios were between
the accepted range of 1.7–2.1. cDNA samples were then diluted
to a concentration of 100ng/µL for use in PCR.
Figure 1. The differences in NRXN expression with age and cortical region. (A–C) Expression by RNAseq relative to reference genes and (D–F) expression by qPCR
(relative to the same reference genes), in four different cortical regions; anterior (A), central (C), posterior (P), and temporal (T) at different ages postconception. (G)
The precise locations of the four sampling regions. Error bars represent standard errors of the mean. Statistically significant differences in expression between
regions at a given age are marked with an asterisk (one-way ANOVA, P < 0.05). RNAseq and qPCR data revealed broadly the same expression patterns with a slight
tendency toward increased expression in the temporal cortex at all ages. (H and I) Changes in expression with age for all pooled cortical samples. Blue lines mark
statistically significant positive correlations showing NRXN1 expression increases with age. NRXN2 expression remains relatively high throughout, NRXN3 expres-
sion relatively low.
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RNAseq Methodology
Full details of the origins, collection, preparation, sequencing,
and analysis of the human fetal RNA samples are provided by
Lindsay et al. (2016). The entire RNAseq dataset from which
data were extracted for this study has been deposited at www.
ebi.ac.uk/arrayexpress/experiments/E-MTAB-4840. Briefly, cDNA
was generated from the RNAs using Illumina’s Stranded mRNA
Sample Prep Kit. Four hundred nanograms of total RNA was
used as the input for each sample. The concentration of each
library was determined using the KAPA quantitative real-time
PCR (qPCR) kit (KK4835) and triplicate reactions using three
independent 106-fold dilutions of the libraries. The size profile
of approximately 15% of the libraries was evaluated using an
Agilent Bioanalyzer DNA 1000 chip. The average final library
size was between 272 and 467 bp (includes 120 nucleotides of
adapter sequence). The libraries were sequenced on an Illumina
HiSeq2000. The high-quality reads were then mapped to the
human reference genome hg38 with Tophat2 (Kim et al. 2013).
Reads aligned to genes and exons were counted with BEDTools
(Quinlan and Hall 2010). Read length was 101 bp prior to trim-
ming and, in the majority of cases, 85 bp after trimming with no
reads of <20 bp retained. The minimum number of reads exam-
ined per sample was 63 million and the average was 90 million.
Differentially expressed genes and exons were then identified
with the Bionconductor package DESeq2 (Love et al. 2014).
Quantitative Real-Time PCR
In order to validate the RNAseq findings, the expression levels of
the three NRXN genes and three reference genes (β-ACTIN,
GAPDH, and SDHA) (Vandesompele et al. 2002) were measured
by qPCR from 56 samples taken from the four sampled sections
at 8, 10, or 12 PCW (see Table 2). Primers were designed according
to the standard criteria for PCR primer design using the Primer3
(v. 0.4.0) designing program (http://frodo.wi.mit.edu/primer3/).
Primers synthesis and product sequencing for quality control
were performed by Eurofins MWG Operon1 (http://www.
eurofinsgenomics.eu). Table 2 presents the sequence and product
size of each primer used. A SYBR Green-based rtPCR assay was
performed in 7900HT Fast Real-Time PCR system (Applied
Biosystems, Warrington, UK). A total volume of 10 μL qPCR reac-
tion was set up in triplicates, containing 5 μL of 2× SYBR Green
qPCR Master Mix (Invitrogen), 1 μL of the diluted cDNA template,
0.5 μL of each primer (10 ρmol/μL), and 3 μL of Molecular Biology
grade water. A negative control was incorporated by replacing the
cDNA template with Molecular Biology grade water (VWR
International, Lutterworth, UK). A standard thermal cycle protocol
was used as previously described (Ip et al. 2010). The results of
each reaction were analyzed by uploading raw data to the Real-
Time PCR Miner web site (http://www.miner.ewindup.info). This
calculated the reaction efficiency and the fractional cycle number
at threshold (CT) for each reaction (Zhao and Fernald 2005).
Quantitative Comparison of RNAseq and qPCR Data,
and Individual Exon Expression by RNAseq
To make expression data comparable between different method-
ologies (Al-Jaberi et al. 2015), we divided the expression level of
the gene of interest, Reads Per Kilobase of transcript per Million
mapped reads (RPKM) for RNAseq, and CT values for qPCR, by
the geometric mean expression of three reference genes
(β-ACTIN, GAPDH, and SDHA; Vandesompele et al. 2002) to give
relative expression levels in different regions of the cortex at dif-
ferent ages which were then compared by one-way ANOVA fol-
lowed by Tukey’s post hoc test. Expression of the three reference
genes was found, on average, to change little across the different
regions of the cortex or with age, by either RNAseq or qPCR
(Supplementary Fig. 2) validating the choice of these genes.
Expression levels of NRXN-related genes, KHDBRS genes, and
individual NRXN exons (6, 17, 19, and 20; see Supplementary
Fig. 1) were quantified in terms of normalized RPKM per exon
for between 16 and 33 samples for each gene from across the
cortex, right, and/or left hemisphere from 3 fetuses at 9 PCW, 5
fetuses at 11 PCW, and 4 fetuses at 12 PCW. The differences in
expression between genes or exons were tested by one-way
ANOVA followed by Tukey’s post hoc test.
Immunohistochemistry
Deparaffinised coronal and sagittal sections collected on slides
were immersed in 1.5 % hydrogen peroxide/methanol solution
(Merck Millipore, Watford, UK) to block activity of endogenous
peroxidases followed by heat-mediated antigen retrieval treat-
ment in citrate buffer (pH 6.0) before incubating sections with
10% of the appropriate normal serum (Vector Laboratories,
Peterborough, UK) in Tris-buffered saline (TBS) for 10min. For
immunoperoxidase, staining sections were then incubated with
a primary antibody (see Table 3 for sources of antibodies) in TBS
solution overnight at 4°C. Sections were then washed and incu-
bated for 30min with the appropriate biotinylated secondary
antibody (Vector Laboratories, Peterborough, UK), washed then
incubated for 30min with Vectastain Elite ABC kit (Vector Labs)
and developed using 3,3′-diaminobenzidine (Vector Labs).
Sections were dehydrated, cleared, and coverslipped.
Table 1 A summary of the number of tissue samples taken at each
age and location for either RNAseq analysis or qPCR
Age (PCW) Number of samples
Anterior Central Posterior Temporal Total
RNAseq
9 4 3 4 8 19
11 4 3 4 8 19
12 5 3 6 10 24
62
qPCR
8 5 5 5 3 18
10 5 5 5 3 18
11 5 5 5 5 20
56
At each age/location samples were taken from a minimum of two brains as
samples taken from each hemisphere were counted separately.
Table 2 List of primers for qPCR
Gene Forward primer 5′–3′ Reverse primer 5′–3′ Amplicon
size (bp)
NRXN1 aggacattgacccctgtgag ccttcatcccggtttctgta 205
NRXN2 catcctcctctacgccatgt ttgttcttcttggccttgct 165
NRXN3 gctgagaacaaccccaata atgctggctgtagagcgatt 179
*BACTIN ctacaatgagctgcgtgtggc caggtccagacgcaggatggc 271
*GAPDH tgcaccaccaactgcttagc ggcatggactgtggtcatgag 87
*SDHA tgggaacaagagggcatctg ccaccactgcatcaaattcatg 86
*Reference genes BACTIN, β-actin; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; SDHA, succinate dehydrogenase complex subunit A.
Neurexins 1–3 Each Have a Distinct Pattern of Expression Harkin et al. | 219
D
ow
nloaded from
 https://academ
ic.oup.com
/cercor/article-abstract/27/1/216/2737439 by U
niversity of N
ew
castle user on 24 January 2020
For immunofluorescent double labeling, including using two
antibodies from the same species, the following method was
employed (Goto et al. 2015; Harkin et al. 2016). Sections were
incubated with the first primary antibody as before, washed and
incubated with the appropriate ImmPRESS HRP IgG (Peroxidase)
Polymer Detection Kit (Vector Labs) for 1 h, washed then incu-
bated for 30min with tyramide signal amplification (TSA) fluores-
cein plus system reagent (Perkin Elmer, Buckingham, UK). After
washing but before application of a second primary antibody,
sections were subjected to heat-mediated antigen retrieval in
boiling citrate buffer (pH 6.0). This removed the first set of pri-
mary and secondary antibodies employed but left fluorescent
tyramide covalently bound to the tissue section. The method
above was repeated for the detection of this second primary anti-
body except that TSA rhodamine plus was used for detection.
Sections were then washed, counterstained with 4′,6-diamidino-
2-phenylindole, dihydrochloride (Thermo Fisher Scientific) and
coverslipped with Vectashield (Vector Labs).
Results
Quantitative Analysis of mRNA Reveals Distinct
Patterns of NRXN Gene Expression
Sixty-three samples of RNA, taken from four different regions
of the cortical surface (see Fig. 1G) at either 9, 11, or 12 PCW
were sequenced and mapped. All three NRXNs were expressed
in all regions and at all ages, although NRXN3 was consistently
expressed at lower levels than NRXN 1 and 2 (Fig. 1A–C). NRXN
1 and 2 were found to be highly expressed (top quartile of all
protein coding genes); however, NRXN3 was expressed at levels
we would still expect to be detectable by histological methods
(Al-Jaberi et al. 2015). For all three NRXNS, at all ages, expres-
sion tended to be higher in the temporal cortex, but this only
reached statistical significance for NRXN2 at 9 PCW and 11 PCW
compared to central regions of the cortex (Fig. 1A,B) and for
posterior cortex compared to central cortex at 11 PCW (Fig. 1B).
For NRXN1, at 12 PCW, expression was also significantly higher
in temporal cortex compared to anterior cortex (Fig. 1C). In
order to confirm these results, a separate set of 56 samples of
RNA were taken for qPCR analysis, although at slightly different
age points (8, 10, and 12 PCW, Fig. 1D–F).
Results from qPCR very largely confirmed the findings by
RNAseq except that increased expression in the temporal cortex
was not as marked, although for NRXN1 it was significantly
higher than expression in the posterior cortex at 10 PCW
(Fig. 1E). Somewhat anomalously, expression of NRXN1 in the
anterior cortex was markedly high at 12 PCW (Fig. 1F). What was
apparent from the qPCR study, with its wider age range, was
that whereas expression of NRXN2 remained consistently high
over time, NRXN1 expression increased with age. Results from
all regional samples were pooled and plotted against age for
both RNAseq and qPCR. It was clear that in both cases, NRXN one
expression increased significantly with age (Fig. 1H,I). However,
NRXN2 expression remained constantly high, andNRXN3 expres-
sion consistently lower.
In summary, there were no marked differences in expression
between different regions of the cortex detected by either
RNAseq or qPCR although expression tended to be higher in tem-
poral cortex, and to a lesser extent frontal cortex, than in central
or posterior regions. Although it has been suggested that fronto-
temporal circuitry may be primarily “at risk” in neurodevelop-
mental conditions (Scott-Van Zeeland et al. 2010; Catani et al.
2016), we have found no strong evidence that NRXNs are pre-
dominantly expressed there, such that mutations in NRXN genes
might have a more a deleterious effect in these cortical regions.
Expression of NRXN-Associated Genes
RNAseq data were then analyzed to determine the levels of
expression of proteins associated with NRXNs at synapses,
many of which are also candidate susceptibility genes for neuro-
developmental disorders (Ye et al. 2010; Bang and Owczarek
2013). We categorized them according to their location at the
synapse, the level of expression and developmental stage (see
Table 4). We found that many, but not all, were expressed at
similarly high levels as NRXNs 1 and 2, suggesting that they
could be potential binding partners for NRXNs in the developing
cortex. Expression of postsynaptic binding partner NLGN2 was
twice that of NRXNs 1 and 2 (Table 4 and data not shown). NGLN3
and leucine-rich repeat transmembrane 2 (LRRTM2) were highly
expressed and NGLN1 increased in expression with age. LRRTMs
3 and 4, NLGN4Y and X were moderately expressed but LRRTM1
showed lower expression. At the presynaptic membrane cerebel-
lin 1 (CBLN1) was highly expressed at the earlier stage. Genes
associated with the postsynaptic density, Disks large homolog 4
(DLG4) and SH3 and multiple Ankyrin repeat domains 1 (SHANK1)
Table 3 Primary antibodies employed
Antigen Supplier Previous use in human Dilution Species
NRXN1α+β Santa Cruz. Sc14334 Western blot: Kim et al. (2008). 1/300 Goat polyclonal
Immunohistochemistry: Zhang et al. (2013).
NRXN2α AbCam. Ab34245 Immunohistochemistry: Borsics et al. (2010). 1/2000 Rabbit polyclonal
NRXN3α+β Sigma-Alldrich Prestige. HPA 002727 Tested by human protein atlas including
immunohistochemistry.
1/300 Rabbit polyclonal
CASK AbCam. ab126609 Immunohistochemistry: Wei et al. (2014). 1/350 Rabbit monoclonal
KHDBRS1 Santa Cruz. Sc333 1/1500 Rabbit polyclonal
KHDBRS2 Dr Peter Scheiffele 1/10 000 Rabbit polyclonal
KHDBRS3 Dr Peter Scheiffele 1/5000 Guinea pig polyclonal
PAX6 Covance, PRB-278P Immunohistochemistry: Bayatti et al. (2008). 1/1500 Rabbit polyclonal
TBR1 AbCam Ab31940 Immunohistochemistry: Bayatti et al. (2008). 1/1500 Rabbit polyclonal
GAP43 Sigma-Alldrich G9264 Immunohistochemistry: Bayatti et al. (2008). 1/10 000 Mouse monoclonal
SYP Sigma-Alldrich Immunohistochemistry: Bayatti et al. (2008). 1/1000 Mouse monoclonal
For antigenic sites of anti-NRXN antibodies, see Supplementary Fig. 1. anti-NRXN1 has also been tested against recombinant mouse NRXN1 expressed in a human
kidney cell line (Cheng et al. 2009).
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were highly expressed although SHANK2 and SHANK3 exhibited
moderate levels of expression. Genes normally associated with
synaptic vesicles, synaptophysin (SYP) and synapse-associated pro-
tein 25 kDa (SNAP25) were very highly expressed and CASK, which
connects neurexins to the exocytotic machinery, also showed
high levels of expression similar to NRXNs 1 and 2 (Table 4).
Localization of Expression of NRXN Proteins
by Immunohistochemistry
The specificity of our antibodies was first tested by immunos-
taining sections of adult human cerebral cortex in comparison
with SYP immunoreactivity. Our antibodies to NRXN1 and three
were generated against peptide sequences common to both α
and β isoforms, but the antibody to NRXN2 was raised against
the α form only (Supplementary Fig. 1). All anti-NRXN antibodies
and anti-SYP produced immunoreactivity in gray matter neuro-
pil which was generally punctate in appearance, suggestive of
presynaptic terminals and/or synaptic contacts (Fig. 2A–D).
However, the density of punctate staining was lower for NRXN1
and there was additional immunoreactivity in many cell nuclei.
NRXN2α immunoreactivity also appeared in the cytoplasm of
some cells including oligodendrocyte-like cells in the white mat-
ter (not shown). The density of immunoreactivity was greatly
reduced in the white compared to gray matter for all four pro-
teins (not shown). In sections of 12 PCW fetal cortex, SYP immu-
noreactivity revealed a small amount of neuropil in the pSP
likely to contain the earliest synapses (Fig. 2E; Bayatti et al. 2008).
Only NRXN2α immunoreactivity was strongly expressed in the
neuropil of this region (Fig. 2G). Both NRXN1 and NRXN3 were
expressed in the cell bodies, their immediate processes and, par-
ticularly for NRXN1, some nuclei of many immunoreactive cells
in the pSP and the overlying CP. Neuropil staining was very weak
for NRXN1 but some punctate staining in the pSP and CP was
detectable for NRXN3. Because of the unexpected nuclear label-
ing observed with anti-NRXN1 antibody, we tested immunos-
taining with the antibody in the presence of blocking peptide
according to the manufacturer’s instructions (Santa Cruz). All
immunostaining was abolished suggesting that the NRXN1 anti-
genic site was present in the nucleus (Supplementary Fig. 3).
We proceeded to investigate NRXN immunoreactivity over
the age range 8–12 PCW in comparison to the expression of other
markers for the different cortical layers (Fig. 3). As has been pre-
viously demonstrated (Bayatti et al. 2008), PAX6 identifies radial
glial cells in the proliferative ventricular (VZ) and subventricular
(SVZ) zones, TBR1 immunoreactivity identifies postmitotic neu-
rons in the SVZ, migrating through the intermediate zone (IZ)
and in the pSP CP and outer MZ. GAP43 and SYP immunoreactiv-
ity are localized to growing axons, growth cones and newly
forming synaptic terminals and delineate the MZ and pSP (SYP
more than GAP43) and IZ (GAP43more than SYP).
Each NRXN showed a distinct pattern of immunoreactivity.
At 8 PCW, NRXN1 expression was strongest in cells lining the
apical surface of the VZ, in the pSP, and in the CP, particularly at
the border with the MZ, and in the MZ itself and was predomin-
antly cytoplasmic or membranous, rather than nuclear (Figs 3A
and 4A). Immunofluorescent double labeling revealed NRXN1
expression around the margins of PAX6-positive progenitor cells
in the VZ (Fig. 4A) but no strong colocalization with SYP in the
pSP (Fig. 4B). Similarly, by 12 PCW, there was no expression in
Table 4 Summary of expression of mRNA for neurexins and associated proteins
Protein location Expression (normalized RPKM) 9 PCW 11–12 PCW
Presynaptic/extracellular High: 5–25% (40–160) CBLN1 NRXN1
NRXN1 NRXN2
NRXN2
Moderate: 25–50% (10–40) NXPH1 NXPH1
CBLN1
NRXN3
Low: 50–75% (0.4–10) CBLN2 CBLN2
NRXN3
Presynaptic/intraterminal Very high: top 5% (>160) SNAP25 SNAP25
SYP SYP
High: 5–25% (40–160) CASK CASK
Postsynaptic/extracellular Very high: top 5% (>160) NLGN2 NLGN2
High: 5–25% (40–160) LRRTM2 LRRTM2
NLGN3 NLGN1
NLGN3
Moderate: 25–50% (10–40) LRRTM3 LRRTM3
LRRTM4 LRTMM4
NLGN1 NLGN4X
NLGN4X NLGN4Y*
NLGN4Y*
Low: 50–75% (0.4–10) LRRTM1 LRRTM1
Postsynaptic/intracellular Very high: top 5% (>160) DLG4 DLG4
High: 5–25% (40–160) SHANK1 SHANK1
Moderate: 25–50% (10–40) SHANK2 SHANK2
SHANK3 SHANK3
Protein location describes its location in the mature central nervous system. Extracellular means at least part of the molecule is an extracellular domain. Expression
is the mean across all cortical regions. Percentage values indicate into which quartile range for all protein coding expression data the expression values fall. RPKM
values are indicative and not exact. *NLGNY means from male samples only, female samples gave mean expression 0.11 range 0.07–0.45. NXPH, neurexophilin.
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the network of neurites in the MZ, pSP, and IZ that was strongly
immunopositive for GAP43 and SYP (Fig. 4C,D). However, NRXN1
was expressed in many but not all cell bodies, in all layers of
cortical wall and, expression was strongest in the VZ (Figs 3B
and 4C) and in the immature neurons of the MZ and the superfi-
cial CP and appeared to be expressed in cell nuclei (Figs 3B and
4D,E). Many cells coexpressed TBR1 and NRXN1 but NRXN1
expression predominated in the superficial CP, TBR1 in the
lower CP, with cells expressing one, the other or both in the pSP
(Fig. 4E). There was no evidence for more intense NRXN1 immu-
noreactivity in the frontal or temporal lobes (not shown).
NRXN2α immunoreactivity was expressed strongly through-
out the cortical wall at 8 PCW (Fig. 3A) both in and around cells,
but not in their nuclei, and in networks of processes away from
the cell bodies. It was colocalized both with PAX6-positive pro-
genitors and TBR1-positive postmitotic neurons (Fig. 5A,B).
Although present in the pSP it showed comparatively weak
colocalization with SYP but exhibited stronger expression and
colocalization with GAP43, particularly in the IZ (Figs 3A and
5C,D). It was also strongly coexpressed with CASK, particularly
in the IZ (Fig. 5E). This pattern of expression was little changed
by 12 PCW (Fig. 5F–H) although colocalization with SYP was
possibly more evident by this stage. Expression of CASK
became much stronger in the proliferative SVZ and VZ at 12
PCW where it was colocalized with all three NRXNs (Fig. 3B).
At 8 PCW, NRXN3 immunoreactivity was almost entirely
confined to the CP and MZ (Figs 3A and 6A,B). By 12 PCW, there
was an increase in nuclear staining as was observed for
NRXN1. NRXN3 immunoreactivity was also detected in the pro-
liferative zones where it colocalized with PAX6-positive pro-
genitors in the upper part of the VZ in particular (Figs 3B and
6C) and with NRXN2α in the VZ, and to a lesser extent, in the
SVZ (Fig. 6F). NRXN2α expression was present at the apical sur-
face of the VZ where NRXN3 was absent. In the CP, NRXN3
expression was colocalized with TBR1, NRXN1, and NRXN 2α
(Fig. 6D,F,G) but in all cases NRXN3 expression was relatively
stronger in the superficial part of the CP near the border with
the MZ, where TBR1 in particular was more weakly expressed
(Fig. 6D). There was very little colocalization between NRXN3
and SYP in the pSP and MZ, although NRXN3 positive cells
were present in these layers (Figs 3B and 6E).
Expression of KHDBRS mRNA and Proteins
and Alternative Splicing of NRXNs
From the RNAseq data, it can be seen that all three KHDBRS
genes were expressed in the developing cortex (Fig. 7A).
KHDBRS1 showed very high levels of expression, four to five
times greater than the highest expression levels measured for
NRXN1 and 2. KHDBRS2 and 3 exhibited expression levels com-
parable to NRXNs, although KHDBRS3 showed slightly higher
expression than KHDBRS2. There was no significant change in
expression levels with age or with cortical location (Fig. 7A).
In general terms, protein expression reflected mRNA expres-
sion. Immunoreactivity for KHDBRS1 (SAM68) was intense and
appeared to be present in every cell, proliferative and postmito-
tic, and throughout all compartments of the cerebral cortex
and ventral telencephalon, between 8 and 12 PCW (Fig. 7B).
KHDBRS2 (SLM1) showed the lowest levels of immunoreactiv-
ity, in concordance with the findings from RNAseq. At 8 PCW
most cells of the MZ, CP, and pSP were immunopositive for
KHDBRS2. Isolated immunostained cells were also seen in the
IZ and SVZ but not the VZ. By 12 PCW, KHDBRS2 immunoreac-
tive cells were predominant in the deeper part of the CP, pSP,
and MZ, but rare in the superficial CP. Scattered positive cells
were observed in the IZ and SVZ along with a small number in
the VZ. In the ventral telencephalon, KHDBRS2 expression was
greater in the proliferative zone of the lateral ganglionic emi-
nence (LGE) than the medial ganglionic eminence (MGE) a few
Figure 2. Immunohistochemistry for SYP and the NRXNs in paraffin sections from adult (A–D) and fetal (E–H) cerebral cortex. (A) Punctate SYP immunoreactivity con-
fined to presumptive synaptic terminals in the gray matter neuropil. In the fetal cortex (E) such punctate staining is largely confined to the pSP. All three NRXNs also
exhibited punctate staining (B–D) in adult cortex, although at a lower density for NRXN1 with evidence of nuclear staining (arrow, B). In the fetal cortex, NRXN1 was
expressed in cell bodies, processes, and some nuclei (arrows) of many immunoreactive cells in the pSP and CP but without punctate staining (F). NRXN2, however,
exhibited punctate staining in the pSP in particular (G). NRXN3 was expressed in cell bodies and processes mostly in the CP, with some punctate immunoreactivity,
largely in the pSP (H). Scale bar = 50 µm.
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Figure 3. A comparison of NRXN immunoreactivity with other cell markers across the cortical wall at 8 PCW (A) and 12 PCW (B). H&E, hemotoxylin and eosin
stained; o, outer; i, inner. Note that PAX6 revealed radial glial progenitor cells; TBR1, postmitotic neurons; SYP, CASK and GAP43 neurites of the pSP and IZ. NRXN1
and 3 predominantly localized to layers with a high-cellular density, whereas only NRXN2α predominantly colocalized with synaptogenic zones and growing axons.
(C) Internal capsule in the ventral forebrain in which bundles of growing axons were GAP43 positive, NRXN1 and 3 negative, and partially positive for NRXN2α (arrow)
although some axon bundles appeared negative (*). Scale bars: A and B, 200 µm; C, 500 µm.
Figure 4. Colocalization of NRXN1 immunoreactivity (red) with phenotypic markers (green) by immunofluorescence. At 8 PCW NRXN1 immunoreactivity was present
in cytoplasm/membranes around PAX6-positive radial glia, particularly near the apical ventricular surface (A) but showed little colocalization with SYP in the pSP at
either 8 PCW (B) or 12 PCW (D) nor with GAP43 in growing axons of the IZ (C). However, there was strong colocalization (orange–yellow) with TBR1 in the postmitotic
neurons of the CP. Scale bars = 100 µm.
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scattered positive cells were also seen in the postmitotic man-
tle zone (Fig. 7D).
KHDBRS3 (SLM2/T-STAR) showed higher levels of immuno-
reactivity than KHDRBS2. At 8 PCW, in addition to strong
immunostaining in the CP, MZ, and pSP/IZ, there was wide-
spread moderate immunoreactivity in the proliferative layers
(Fig. 7C). By 12 PCW, a complex pattern of immunostaining had
emerged in the CP, with more immunopositive cells in the
superficial layer and also close to the boundary with the pSP,
but with a band of weaker immunoreactivity in the middle of
the CP. Weak to moderately immunoreactive cells were present
throughout the IZ and proliferative layers (Fig. 7E). In the gan-
glionic eminences, immunopositive cells were present through-
out the proliferative zones of the LGE and MGE, with scattered
cells present in the postmitotic mantle zone (Fig. 7E). In the
mouse, KHDBRS2 and 3 are expressed in distinct populations of
cortical interneurons with KHDBRS2 restricted to a small
subpopulation of calbindin positive interneurons (Iijima et al.
2014). The reduced expression of KHDBRS2 compared to
KHDBRS3, particularly in the MGE suggests that in human also
that KHDBRS proteins may segregate to different interneuron
precursors, but this was not explored further. However, the
extensive expression of KHDBRS2 protein in the CP differs from
the lack of expression of this protein by the glutamatergic neu-
rons of the adult mouse neocortex (Iijima et al. 2014).
Having established expression of KHDBRS proteins we reex-
amined the RNAseq data at the level of expression of individual
exons of the NRXN genes in cortical samples at 9 and 12 PCW.
Exons 6 and 17, which belong to α NRXNs only, and exons 19
and 20, which are found in both α and β isoforms, were chosen.
Alternative splicing by KHDBRS proteins occurs at alternative
splice site (AS) 4 and results in suppression of expression of
exon 20 compared to exon 19 (Rowen et al. 2002). One-way
ANOVA established that there were statistically significant
Figure 5. Colocalization of NRXN2 immunoreactivity (red) with phenotypic markers (green) by immunofluorescence. At 8 PCW NRXN2 was ubiquitously expressed
and surrounded both PAX6-positive nuclei of progenitor cells (A) and TBR1-positive nuclei of postmitotic neurons (B) (green). In the pSP and IZ, NRXN2 showed stron-
ger colocalization (yellow) with GAP43 (C) and particularly CASK (E) than with SYP (D). At 12 PCW NRXN2 and GAP43 are strongly colocalized (yellow) in the pSP and
IZ but not the MZ (F). NRXN2 also colocalized with SYP in pSP and IZ (G). As at 8 PCW, many cells coexpressed NRXN2 in the cytoplasm and processes surrounding
PAX6-positive nuclei, especially in the oSVZ and VZ (H). iSVZ and oSVZ, inner and outer subventricular zone. Scale bars = 100 µm in A–E and F–H.
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differences in expression between exons for all three NRXNs (at
9 PCW for NRXN1, P < 0.0001; NRXN2, P < 0.001; NRXN3, P < 0.03;
at 12 PCW for NRXN1, P < 0.0001; NRXN2, P < 0.0001; NRXN3,
P < 0.04). Post hoc comparisons revealed that at 9 PCW expres-
sion of NRXN1 exon 19 was significantly higher than expression
of exon 17 or exon 20 (P < 0.01) suggesting that a modest
amount of NRXN1β was transcribed and there was a significant
two-thirds reduction in expression of exon 20 (Fig. 7F). By 12
PCW, the differences in expression between exon 19 and exons 6
and 17 were significant (P < 0.01) and larger than at 9 PCW, show-
ing that NRXN1β expression had increased. Exon 20 continued to
show a high degree of suppression of expression (Fig. 7F,G).
For NRXN2, at both ages studied, expression of exon 19 was
significantly higher than all the other exons studied (P < 0.01).
Figure 6. Colocalization of NRXN3 immunoreactivity (red) with phenotypic markers (green) by immunofluorescence. At 8 PCW NRXN3 expression was almost com-
pletely confined to the CP and separated from SYP immunoreactivity (A) showing only weak colocalization with NRXN2 in the CP (pale green, B). At 12 PCW NRXN3
was expressed in the proliferative zones and colocalized (yellow) with PAX6 (C) and in the CP was colocalized with TBR1, especially in the deeper layer (dCP) (D).
NRXN3 did not colocalize with SYP (E) but was coexpressed with NRXN2 in the dCP (F). NRXN1 and 3 were colocalized throughout the cortical wall at 12 PCW but espe-
cially strongly in the CP and VZ (G). Scale bar = 200 µm.
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Figure 7. KHDRBS 1–3 expression in human early fetal forebrain and suppression of NRXN exon 20. (A) RNAseq analysis found very high expression of KHDBRS1 main-
tained with age, and moderate expression of KHDRBS2 and 3 which increased with age (dotted trend lines indicate a significant correlation, P < 0.001). (B) Patterns of
KHDRBS immunoreactivity reflected mRNA expression; KHDBRS1 immunoreactivity was intense throughout the telencephalon at 10 PCW. (C) At 8 PCW, many
KHDBRS2 positive cells were observed in the MZ, CP, and pSP, isolated cells were also seen in the IZ and SVZ; there was stronger immunostaining for KHDBRS3 in the
CP, MZ, and pSP/IZ, with widespread moderate immunoreactivity in the SVZ and VZ. At 12 PCW, KHDBRS2 immunoreactive cells were predominant in the deeper
part of the CP (dCP), pSP and MZ, but rare in the superficial CP (sCP). Scattered positive cells were observed in the IZ and SVZ along with a small number in the VZ
(D and D1). For KHDBRS3, a complex pattern of immunostaining was observed in the cortex with more immunopositive cells in the sCP and close to the boundary
with the pSP, but with a band of weaker immunoreactivity in the middle of the CP. Weak to moderately immunoreactive cells were present throughout the IZ and
proliferative layers (E and E1). KHDBRS2 expression was greater in the proliferative zone of the LGE than the MGE with a few scattered positive cells present in the
postmitotic mantle zone (D and D2). KHDBRS3 immunopositive cells were present throughout the proliferative zones of the LGE and MGE, with scattered cells
observed in the postmitotic mantle zone (E and E2). Med and Lat Crtx, medial and lateral cortex; VP, ventral pallium, border between cortex and ganglionic emi-
nences. (F and G) Expression of four exons, present in all three NRXNs, were chosen for analysis; 6 and 17 that are in the alpha (α) isoforms only of NRXN proteins,
and 19 and 20 translated in both alpha and beta (β) isoforms. KHDBRS proteins splice NRXN mRNA to exclude exon 20. Statistically significant reductions in exons 6 or
17 compared to 19 indicate less expression of α compared to the β isoforms, and significant reductions in 20 compared to 19 indicates suppression of exon 20 expres-
sion by KHDBRS proteins (*P < 0.05, **P < 0.01 by Tukey’s post hoc test). Error bars indicate standard errors of the mean. Scale bars = 750 µm for B; 200 µm for C; 1mm
for D and E; 250 µm for D1, D2, E1, and E2.
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Relative production of NRXN2β compared to α isoforms seems
to be greater than for NRXN1 isoforms especially at 9 PCW, but
the degree of suppression of exon 20 is not as marked as for
NRXN1 (Fig. 7F,G). For NRXN3, the expression levels of each
exon were low and not markedly different, except that we
observed significantly greater expression of exon 19 compared
to 17 at 9 PCW; evidence for some production of the NRXN3β
isoform, at least at this stage of development (Fig. 7F,G).
Discussion
This study has confirmed that all three NRXN genes show sig-
nificant levels of expression in the early developing human
cerebral cortex prior to extensive synapse formation, as sug-
gested by preliminary gene expression studies (Ip et al. 2010;
Kang et al. 2011), and as was previously shown in the mouse by
in situ hybridization (Puschel and Betz 1995). Each NRXN had a
unique expression pattern, which suggests that they each may
have different functions. NRXN1 and 3 protein showed broadly
similar patterns of expression, strongest in the CP, although
only NRXN1 expression increased with age whereas NRXN3
expression was relatively low. This is in partial disagreement
with Konopka et al. (2012) who found that NRXN1 was predom-
inantly expressed in postmitotic cortical cells whereas NRXN3
was predominantly expressed in proliferating cells in both
mid-gestation tissue sections and normal human neural pro-
genitor cells differentiating in vitro. More recently, Jenkins et al.
(2015) have demonstrated by qPCR that NRXN1 expression, in
both α and β isoforms, increases in expression from 14 PCW
until birth in the prefrontal cortex.
NRXN2 was more highly expressed at earlier stages than
NRXN1 or NRXN3 throughout, and although present throughout
the cortical wall NRXN2α was the only NRXN to strongly coloca-
lized with neurites in the IZ and synaptogenic pSP. This diversity
in expression patterns is unexpected as it is generally believed
that there is no functional differentiation between α NRXNs
based on “rescue” experiments in transgenic mice (Zhang et al.
2005) although this only probed their function in neurotransmit-
ter release at the synapse. However, there are other respects in
which NRXNs 1 and three diverge from NRXN2; a phylogenetic
tree for the NRXN protein family demonstrates that NRXNs 1
and 3 are more closely related to each other than either is to
NRXN2 (Reissner et al. 2013). Whereas NRXNs 1 and 3 are
unusually long genes, greater than one Mega base pairs (Mbp) in
length, the NRXN2 gene, despite having a very similar number of
exons and amino acids in the protein, is only 0.117Mbp in length
(Rowen et al. 2002; Tabuchi and Südhof 2002). The smaller length
of NRXN2may permit transcription to be completed within a cell
cycle in dividing cells (Rowen et al. 2002: Reissner et al. 2013)
explaining its increased expression compared to NRXNs 1 and 3
at earlier stages of development and in proliferative layers. The
largest gene NRXN3, on the other hand, showed the greatest
degree of restriction to postmitotic layers.
Regulation of Alternative Splicing at AS4 and Synapse
Formation
It is well established that presynaptic NRXNs on growing axons
can interact with NLGNs expressed on growing dendrites to sta-
bilize the postsynaptic site and establish vesicle accumulation at
the presynaptic site (Graf et al. 2004; Chen et al. 2010). Although
synapses are rare in the early developing cortex, they can be
detected by electron microscopy in the MZ and pSP (but not the
CP) and increase substantially over the period of the present
study (Kostovic´ and Rakic 1990). Proteins associated with synap-
ses such as SYP, vesicular GABA transporter, and CASK have
also been detected in the pSP at these ages by immunohisto-
chemistry (Bayatti et al. 2008; Figs 3–6, present study). Therefore,
it is reasonable to suppose that NRXN expression could reflect
the nascent synaptogenesis occurring at this stage.
Regulation of Nrxn exon 20 expression at AS4 generates
+ or – isoforms that show differential binding to cell-type-
specific postsynaptic partners (Baudouin and Scheiffele 2010;
Vuong et al. 2016). KHDBRS proteins bring about splicing at AS4
and there is evidence of Khdbrs3 regulated exon skipping dur-
ing mouse forebrain development (Ehrmann et al. 2013). NRXNβ
AS4– isoforms preferentially bind NLGN1 concentrated at gluta-
matergic synapses, whereas NRXNα AS4– and NRXNβ AS4+ iso-
forms preferentially bind NLGN2 at GABAergic and glycinergic
synapses (Chih et al. 2006). Thus, exclusion of exon 20 in differ-
ent α or β isoforms might be required to induce formation of
both major classes of synapse in the cortex. KHDBRS1 was
found to be abundantly expressed in the developing cortex, but
in mouse, KHDBRS1 only affects Nrxn splicing in the presence
of depolarizing neuronal activity (Iijima et al. 2011). As in the
16–20 PCW human cortex, there is only significant neuronal
activity in the subplate and the CP is largely quiescent (Moore
et al. 2009), it is not expected that KHDBRS1 makes a significant
contribution to NRXN splicing in our study.
However, both KHDBRS2 and 3 constitutively affect Nrxn spli-
cing: ablation of either leads to a severe reduction in the Nrxn
AS4– isoform in neurons or brain areas where they are typically
expressed ( Ehrmann et al. 2013; Iijima et al. 2014; Traunmuller
et al. 2014). We observed expression of both these proteins, par-
ticularly in the CP and pSP, along with significant reduction in
exon 20 expression, which we predict could occur in NRXN1α
and NRXN2α at all ages studied, NRXN3α at 12 PCW and also in β
isoforms of NRXN1 and 2 (Fig. 7F,G). GABAergic synapses are
likely to be present in the human pSP at this stage of develop-
ment (Bayatti et al. 2008) and our data suggest that both NRXNα
AS4– and NRXNβ AS4+ isoforms and NLGN2, which interact in
their formation (Chih et al. 2006: Vuong et al. 2016) could be
expressed in the pSP at this stage of development. NRXN2α
immunoreactivity was observed within synaptogenic zones.
NRXNα appears important for GABAergic synapse assembly as
triple Nrxnα knock-out mice show a 50% reduction in cortical
GABAergic synapse density (Missler et al. 2003). Early cortical
network activity also relies upon glutamate receptor mediated
activity (Kilb et al. 2011) and our mRNA expression data suggest
the proteins required for glutamatergic synapse formation,
NLGN1, NRXN1β AS4–, and NRXN2β AS4– (Chih et al. 2006) could
also be present, although their protein expression was not exam-
ined in this study.
NRXNs, Vesicles and Axon Growth
Alpha NRXNs interact with components of the exocytosis
machinery indirectly via binding to CASK and synaptotagmin
(O’Connor et al. 1993; Hata et al. 1996; Reissner et al. 2013). They
are one of the receptors for α-latrotoxin which causes uncon-
trolled exocytosis (Südhof 2001) and knock-out of Nrxnα greatly
reduces spontaneous and evoked neurotransmitter release at all
synapses in the mouse brain (Missler et al. 2003). Although
NRXN2α colocalized with SYP, our marker for presynaptic term-
inals, in the pSP and MZ, there appeared to be stronger colocali-
zation with GAP43 in the IZ of the cortex dorsally and the
internal capsule ventrally (Fig. 3) where growing axons mostly
emanating from CP neurons are located at this stage (Ip et al.
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2011). There was also strong colocalization of NRXN2α and CASK
in growing axons. The fusion of intracellular vesicles with the
external membrane at the growth cone provides a mechanism
for addition of membrane and guidance receptors to the leading
filopodia (Tsaneva-Atanasova et al. 2009) and there is increasing
evidence for the role of synapse-related SNARE (soluble N-
ethylmaleimide-sensitive fusion attachment protein receptor)
proteins in the growth of neurites (Kunwar et al. 2010;
Zylbersztejn and Galli 2011). NRXN1β has also been shown to
promote neuritic outgrowth in concert with NGLN1 and activa-
tion of fibroblast growth factor receptor-1 (Gjørlund et al. 2012).
NRXNs and Other Forms of Intercellular Connections
NRXNs appear not to be just confined to synapses of the nervous
system. NRXNs can form a stoichiometric complex with dystro-
glycan, a ubiquitously expressed transmembrane protein linking
cytoskeletal actin to the extracellular matrix. Dystroglycan extra-
cted from brain, heart, and skeletal muscle can interact with
NRXN1 (Sugita et al. 2001) and it was found that cardiac isoforms
of NRXN3 participate in a complex involving dystroglycan and
proteins of the extracellular matrix, presumably involved in
intercellular connections (Occhi et al. 2002). Alternative splicing
at the α isoform-specific AS2 regulates binding of NRXNαs to dys-
troglycan (Sugita et al 2001). Dystroglycan expression in the
developing mouse cerebral cortex at embryonic day 15, equiva-
lent to the stage of development studied here, is confined to
both the CP and the apical surface of the VZ (Lathia et al. 2007)
reminiscent of the pattern of NRXN1 immunoreactivity we have
observed (Figs 3 and 4). The competitive interaction of dystrogly-
can and neurexophilin1 with NRXN1α controls the rate of prolif-
eration of human hematopoietic stem cells (Kinzfogel et al.
2011). As radial glial cells predominantly undergo cell division at
the apical surface of the VZ (Taverna and Huttner 2010; Harkin
et al. 2016) and neurexophilin1 is expressed in the cortex at this
stage of development (Table 2), we hypothesize that NRXN1α in
particular may interact with the extracellular matrix at tight
junctions at the apical surface of the VZ, participating in the con-
trol of progenitor cell proliferation, and may also interact with
dystroglycan in the CP.
NRXNs and Cell Migration
Expression of NRXN protein in cells of the VZ, SVZ, and IZ may be
an indication of its requirement in cell migration away from the
proliferative zones. Indeed, NRXN expression also tended to be
higher in the outer part of the CP, where new neurons are arriv-
ing, compared to the inner CP where older cells have settled hav-
ing finished migration (Bystron et al. 2008). Cell adhesion
molecules are important for neuronal migration (Maness and
Schachner 2007) and molecules such as cadherins, for instance,
also found at the synapse in the mature nervous system, are
regarded as integral to the migration process (Redies et al. 2012).
Certainly, the knock down of Cntnap2, which is similar in structure
to NRXNs and classed as an autism susceptibility gene, causes
abnormal neuronal migration, affecting both cortical projection
neurons and interneurons, in transgenic mice (Peñagarikano et al.
2011) resulting in epilepsy and autism-like behavioral deficits. In
cases of human CNTNAP2 gene mutation, cell migration defects,
epilepsy, ASD, and language deficits have all been reported
(Strauss et al. 2006; Alarcón et al. 2008; Scott-Van Zeeland et al.
2010). The large extracellular portion of CNTNAP2, like the NRXNs
(Supplementary Fig. 1), is composed of protein–protein interaction
domains including laminin G and EGF repeats ( Poliak et al. 1999).
CNTNAP2 interacts extracellularly with CNTN2 (TAG-1) which is
expressed early in mouse development and blocking its function
results in migration abnormalities of cortical pioneer neurons and
GABAergic interneurons (Denaxa et al. 2005; Morante-Oria et al.
2003). Potentially, NRXNs may have as yet unappreciated roles in
cell migration, and by extension, neurite outgrowth, processes
which largely share the same molecular machinery (Maness and
Schachner 2007).
Nuclear Localization of NRXN 1 and 3
The observation of NRXN-like immunoreactivity in the nucleus
was unexpected. This is unlikely to be artefactual as, for NRXN1
at least, it was abolished with blocking peptide. Also the detec-
tion of nuclear NRXN expression increased with age which
would not be expected for nonspecific staining. Finally, both
antibodies employed recognize antigenic sties in the highly con-
served c-terminal regions of NRXN1 and NRXN3, rather than
sites in the ubiquitous protein domains of the extracellular parts
of these molecules. Synaptic proteins are often colocalized to the
synapse and the nucleus (Jordan and Kreutz 2009). For instance,
CASK is known to translocate to the nucleus where CASK inter-
acts with TBR1 and regulates the TBR1-dependent transcription
(Hseuh et al. 2000; Wang et al. 2004). CASK immunoreactivity
increased in the CP and proliferative regions at 12 PCW, the
same age at which anti-NRXN immunoreactivity increased in
these zones. CASK binds indirectly to the c-terminal regions of
the NRXNs (Hata et al. 1996). Whether the C-terminal portion of
NRXNs translocate to the nucleus, with or without CASK,
remains a possibility to be further investigated.
NRXN Mutations and Neurodevelopmental Disorders
To what extent has uncovering expression patterns during
early development suggested roles for NRXNs key to under-
standing how mutations may cause deficits in brain develop-
ment? Genetic studies of neurodevelopmental conditions have
shown that the great majority of mutations affect NRXN1α
expression, leaving β expression intact (Reichelt et al. 2012). We
have found that NRXN1 was expressed in substantial amounts
in the developing cortex, with a higher proportion likely to be
expressed in the α form, especially at 9 PCW where there is pro-
tein expression in the VZ. Therefore, mutations in NRXN1α in
early cortical development could cause subtle alterations in
rates and quantity of neuroblast production from radial glia.
A NRXN2 gene mutation in an ASD patient caused the pro-
duction of a truncated protein which, in vitro, did not bind its
NLGN partner or induce synaptic differentiation (Gauthier et al.
2011). The present study has shown that NRXN2α is the isoform
most likely to be involved in induction of synapse differentiation
in the human pSP and MZ; therefore, it is plausible that NRXN2
mutations may cause alterations in subplate development. Even
at the early stages studied here, synaptic connectivity in the pSP
may be generating synchronous oscillatory network activity in a
first step toward the subplate developing into a hub for network
activity to guide cortical development (Kanold and Luhmann
2010). Disruptions to the subplate have been implicated in epi-
lepsy, ASD, and schizophrenia (Bunney et al. 1997; Kostovic´ et al.
2015; Hutsler and Casanova 2016). However, we have provided
equally strong evidence for involvement of NRXN2α in axon out-
growth and pathfinding (see above). It has also been argued
recently that dysregulation of axonal growth and guidance
should be given greater prominence when considering the eti-
ology of ASD, as many candidate ASD-susceptibility genes
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impinge upon these processes (McFadden and Minshew 2013).
Finally, it is worth noting that NRXN3 shows the lowest levels
and the most restricted pattern of expression, and also the
weakest association of gene polymorphisms with neurodevelop-
mental disorders (see Introduction section).
Conclusion
Without discounting the importance of the contribution of
NRXN mutations to synaptic dysfunction in neurodevelopmen-
tal conditions, the present study suggests that there may be
potential roles for NRXNs in many fundamental developmental
processes in the cerebral cortex. All three NRXNs are expressed
at the earliest stages of human cortical development and show
distinct expression patterns. Functional experiments should be
designed to probe potential roles in cell migration and axon
guidance, axon outgrowth, regulation of neuronal proliferation,
and early development of subplate circuitry.
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Funding
The human fetal material was provided by the Joint UK MRC/
Wellcome Trust (grant # 099175/Z/12/Z) Human Developmental
Biology Resource (www.hdbr.org). The RNAseq study was
funded by a grant from UK MRC (grant # MC/PC/13047).
Notes
Lauren Harkin was in receipt of a studentship from the
Anatomical Society. Ayman Alzu’Bi is in receipt of a student-
ship from Yarmouk University, Jordan. Alexandra Ferrara was
supported by a bursary from the British Division of the
International Academy of Pathology. We are grateful to Dr Peter
Scheiffele for the generous gift of antibodies to KHDBRS2 and 3
and to the staff of the HDBR for their skilled assistance. Conflict
of Interest: None declared.
References
Alarcón M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV,
Bomar JM, Sebat J, Wigler M, Martin CL, Ledbetter DH, et al.
2008. Linkage, association, and gene-expression analyses
identify CNTNAP2 as an autism-susceptibility gene. Am J
Hum Genet. 82:150–159.
Al-Jaberi N, Lindsay S, Sarma S, Bayatti N, Clowry GJ. 2015. The
early fetal development of human neocortical gabaergic
interneurons. Cereb Cortex. 25:635–651.
Bang ML, Owczarek S. 2013. A matter of balance: role of neurex-
in and neuroligin at the synapse. Neurochem Res. 38:
1174–1189.
Baudouin S, Scheiffele P. 2010. SnapShot: neuroligin–neurexin
complexes. Cell. 141:908.
Bayatti N, Moss JA, Sun L, Ambrose P, Ward JFH, Lindsay S,
Clowry GJ. 2008. A molecular neuroanatomical study of the
developing human neocortex from 8 to 17 post conceptional
weeks revealing the early differentiation of the subplate and
subventricular zone. Cereb Cortex. 18:1536–1548.
Betancur C. 2011. Etiological heterogeneity in autism spectrum
disorders: more than 100 genetic and genomic disorders and
still counting. Brain Res. 1380:42–77.
Born G, Grayton HM, Langhorst H, Dudanova I, Rohlmann A,
Woodward BW, Collier DA, Fernandes C, Missler M. 2015.
Genetic targeting of NRXN2 in mice unveils role in excita-
tory cortical synapse function and social behaviors. Front
Synaptic Neurosci. 7:3.
Borsics T, Lundberg E, Geerts D, Koomoa DL, Koster J, Wester K,
Bachmann AS. 2010. Subcellular distribution and expression
of prenylated Rab acceptor 1 domain family, member 2
(PRAF2) in malignant glioma: Influence on cell survival and
migration. Cancer Sci. 101:1624–1631.
Boucard AA, Chubykin AA, Comoletti D, Taylor P, Südhof TC.
2005. A splice code for trans-synaptic cell adhesion
mediated by binding of neuroligin 1 to alpha- and beta-
neurexins. Neuron. 48:229–236.
Bullen P, Wilson D. 1997. The Carnegie staging of human
embryos: a practical guide. In: Strachan T, Lindsay S, Wilson
DI, editors. Molecular genetics of early human development.
Oxford: Bios Scientific Publishers.
Bunney BG, Potkin SG, Bunney WE. 1997. Neuropathological
studies of brain tissue in schizophrenia. J Psychiatr Res. 31:
159–173.
Bystron I, Blakemore C, Rakic P. 2008. Development of the
human cerebral cortex: Boulder Committee revisited. Nat
Rev Neurosi. 9:110–122.
Catani M, Dell’Acqua F, Budisavlijevic S, Howell H, Thiebaut de
Schotten M, Froudist-Walsh S, D’Anna L, Thompson A,
Sandrone S, Bullmore ET, et al. 2016. Frontal networks in
adults with autism spectrum disorderBrain. 139:616–630.
Chen SX, Tari PK, She K, Haas K. 2010. Neurexin-neuroligin cell
adhesion complexes contribute to synaptotropic dendrito-
genesis via growth stabilization mechanisms in vivo.
Neuron. 67:967–983.
Cheng S-B, Amici SA, Ren X-Q, McKay SB, Treuil MW,
Lindstrom JM, Rao J, Anand R. 2009. Presynaptic targetting of
α4β2 nicotinic acetylcholine receptors Is regulated by neur-
exin-1β. J Biol Chem. 28:23251–23259.
Chih B, Gollan L, Scheiffele P. 2006. Alternative splicing controls
selective trans-synaptic interactions of the neuroligin-
neurexin complex. Neuron. 51:171–178.
Ching MS, Shen Y, Tan WH, Jeste SS, Morrow EM, Chen X,
Mukaddes NM, Yoo SY, Hanson E, Hundley R, et al. 2010.
Deletions of NRXN1 (neurexin-1) predispose to a wide spec-
trum of developmental disorders. Am J Med Genet B
Neuropsychiatr Genet. 153B:937–947.
Comoletti D, Flynn RE, Boucard AA, Demeler B, Schirf V, Shi J,
Jennings LL, Newlin HR, Südhof TC, Taylor P. 2006. Gene
selection, alternative splicing, and post-translational pro-
cessing regulate neuroligin selectivity for beta-neurexins.
Biochemistry. 24:12816–12827.
Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA,
Kennedy DP, Morgan J. 2007. Mapping early brain develop-
ment in autism. Neuron. 56:319–413.
Cukier HN, Dueker ND, Slifer SH, Lee JM, Whitehead PL, Lalanne E,
Leyva N, Konidari I, Gentry RC, Hulme WF, et al. 2014.
Exome sequencing of extended families with autism reveals
genes shared across neurodevelopmental and neuropsychi-
atric disorders. Mol Autism. 10:1.
Dachtler J, Glasper J, Cohen RN, Ivorra JL, Swiffen DJ, Jackson AJ,
Harte MK, Rodgers RJ, Clapcote SJ. 2014. Deletion of α-neur-
exin II results in autism-related behaviors in mice. Transl
Psychiatry. 4:e484.
Denaxa M, Kyriakopoulou K, Theodorakis K, Trichas G, Vidaki M,
Takeda Y, Watanabe K, Karagogeos D. 2005. The adhesion
molecule TAG-1 is required for proper migration of the
Neurexins 1–3 Each Have a Distinct Pattern of Expression Harkin et al. | 229
D
ow
nloaded from
 https://academ
ic.oup.com
/cercor/article-abstract/27/1/216/2737439 by U
niversity of N
ew
castle user on 24 January 2020
superficial migratory stream in the medulla but not of cortical
interneurons. Dev Biol. 288:87–99.
Ehrmann I, Dalgliesh C, Liu Y, Danilenko M, Crosier M,
Overman L, Arthur HM, Lindsay S, Clowry GJ, Venables J,
et al. 2013. The tissue specific RNA binding protein T-STAR
controls regional splicing patterns of neurexin pre mRNAs
in the brain. PLoS Genet. 9:e1003474.
Etherton MR, Blaiss CA, Powell CM, Südhof TC. 2009. Mouse
neurexin-1alpha deletion causes correlated electrophysio-
logical and behavioral changes consistent with cognitive
impairments. Proc Natl Acad Sci USA. 106:17998–18003.
Feng J, Schroer R, Yan J, Song W, Yang C, Bockholt A, Cook EH Jr,
Skinner C, Schwartz CE, Sommer SS. 2006. High frequency of
neurexin 1beta signal peptide structural variants in patients
with autism. Neurosci Lett. 409:10–13.
Friedman JM, Baross A, Delaney AD, Arbour L, Armstrong L,
Asano J, Bailey DK, Barber S, Birch P, Brown-John M, et al.
2006. Oligonucleotide microarray analysis of genomic imbal-
ance in children with mental retardation. Am J Hum Genet.
79:500–513.
Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF,
Champagne N, Lapointe M, Spiegelman D, Noreau A,
Lafrenière RG, et al. 2011. Truncating mutations in NRXN2
and NRXN1 in autism spectrum disorders and schizophre-
nia. Hum Genet. 130:563–573.
Gerrelli D, Lisgo S, Copp AJ, Lindsay S. 2015. Enabling research
with human embryonic and fetal tissue resources.
Development. 142:3073–3076.
Gjørlund MD, Nielsen J, Pankratova S, Li S, Korshunova I, Bock
E, Berezin V. 2012. Neuroligin-1 induces neurite outgrowth
through interaction with neurexin-1beta and activation of
fibroblast growth factor receptor-1. Faseb J. 26:4174–4186.
Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S,
Zhang H, Estes E, Brune CW, Bradfield JP, et al. 2009. Autism
genome-wide copy number variation reveals ubiquitin and
neuronal genes. Nature. 459:569–573.
Goto S, Morigaki R, Okita S, Nagahiro S, Kaji R. 2015.
Development of a highly sensitive immuno-histochemical
method to detect neurochemical molecules in formalin-
fixed and paraffin embedded tissues from autopsied human
brains. Front Neuroanat. 9:22.
Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. 2004. Neurexins
induce differentiation of GABA and glutamate postsynaptic
specializations via neuroligins. Cell. 119:1013–1026.
Grayton HM, Missler M, Collier DA, Fernandes C. 2013. Altered
social behaviours in neurexin 1α knockout mice resemble
core symptoms in neurodevelopmental disorders. PLoS One.
8:e67114.
Hata Y, Butz S, Südhof TC. 1996. CASK: a novel dlg/PSD95
homolog with an N-terminal calmodulin-dependent protein
kinase domain identified by interaction with neurexins. J
Neurosci. 14:2488–2494.
Harkin LF, Gerrelli D, Diaz DCG, Santos C, Alzu’bi A, Austin CA,
Clowry GJ. 2016. Distinct expression patterns for type II
topoisomerases IIA and IIB in the early foetal human telen-
cephalon. J Anat. 228:452–463.
Harkin LF, Gullon EA, Lindsay S, Clowry GJ. 2015. The expression
of autism susceptibility genes in the earliest stages of human
cerebral cortex development. Int J Dev Neurosci. 47:75.
Hern WM. 1984. Correlation of fetal age and measurements bet-
ween 10 and 26 weeks of gestation. Obstet Gynecol. 63:26–32.
Hu X, Zhang J, Jin C, Mi W, Wang F, Ma W, Ma C, Yang Y, Li W,
Zhang H, et al. 2013. Association study of NRXN3 poly-
morphisms with schizophrenia and risperidone-induced
bodyweight gain in Chinese Han population. Prog Neuropsy-
chopharmacol Biol Psychiatry. 43:197–20.
Hsueh YP, Wang TF, Yang FC, Sheng M. 2000. Nuclear transl-
ocation and transcription regulation by the membrane-
associated guanylate kinase CASK/LIN-2. Nature. 404:298–302.
Hutsler JJ, Casanova MF. 2016. Cortical construction in autism
spectrum disorder: columns, connectivity and the subplate.
Neuropathol Appl Neurobiol. 42:115–134.
Ichtchenko K, Hata Y, Nguyen T, Ullrich B, Missler M, Moomaw C,
Südhof TC. 1995. Neuroligin 1: a splice site-specific ligand for
β-neurexins. Cell. 81:435–443.
Ichtchenko K, Nguyen T, Südhof TC. 1996. Structures, alterna-
tive splicing, and neurexin binding of multiple neuroligins.
J Biol Chem. 271:2676–2682.
Iijima T, Iijima Y, Witte H, Scheiffele P. 2014. Neuronal cell
type-specific alternative splicing is regulated by the KH
domain protein SLM1. J Cell Biol. 204:331–342.
Iijima T, Wu K, Witte H, Hanno-Iijima Y, Glatter T, Richard S,
Scheiffele P. 2011. SAM68 regulates neuronal activity-
dependent alternative splicing of neurexin-1. Cell. 147:
1601–1614.
Ip BK, Bayatti N, Howard NJ, Lindsay S, Clowry GJ. 2011. The
corticofugal neuron-associated genes ROBO1, SRGAP1 and
CTIP2 exhibit an anterior to posterior gradient of expression
in early foetal human neocortex development. Cereb Cortex.
21:1395–1407.
Ip BK, Wappler I, Peters H, Lindsay S, Clowry GJ, Bayatti N. 2010.
Investigating gradients of gene expression involved in early
human cortical development. J Anat. 217:300–311.
Jenkins AK, Paterson C, Wang Y, Hyde TM, Kleinman JE, Law AJ.
2015. Neurexin 1 (NRXN1) splice isoform expression during
human neocortical development and aging. Mol Psychiatry.
21:701–706.
Jordan BE, Kreutz MR. 2009. Nucleocytoplasmic protein shut-
tling: the direct route in synapse-to-nucleus signaling.
Trends Neurosci. 32:392–401.
Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, Sousa AMM,
Pletikos M, Meyer KA, Sedmak G, et al. 2011. Spatio-temporal
transcriptome of the human brain. Nature. 478:483–489.
Kanold PO, Luhmann HJ. 2010. The subplate and early cortical
circuits. Annu Rev Neurosci. 33:23–48.
Kavanagh DH, Tansey KE, O’Donovan MC, Owen MJ. 2015.
Schizophrenia genetics: emerging themes for a complex dis-
order. Mol Psychiatry. 20:72–76.
Kilb W, Kirischuk S, Luhmann HJ. 2011. Electrical activity pat-
terns and the functional maturation of the neocortex. Eur J
Neurosci. 34:1677–1686.
Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, Shen Y,
Lally E, Weiss LA, Najm J, Kutsche K, et al. 2008. Disruption of
neurexin 1 associated with autism spectrum disorder. Am J
Hum Genet. 82:199–207.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL.
2013. TopHat2: accurate alignment of transcriptomes in the
presence of insertions, deletions and gene fusions. Genome
Biol. 14:R36.
Kinzfogel J, Hangoc G, Broxmeyer HE. 2011. Neurexophilin 1
supresses the proliferation of hematopoietic progenitor
cells. Blood. 118:565–575.
Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M,
O’Donovan MC, Erdogan F, Owen MJ, Ropers HH, et al. 2008.
Comparative genome hybridization suggests a role for NRXN1
and APBA2 in schizophrenia. Hum Mol Genet. 17:458–465.
Klein ME, Younts TJ, Castillo PE, Jordan BA. 2013. RNA-binding
protein Sam68 controls synapse number and local β-actin
230 | Cerebral Cortex, 2017, Vol. 27, No. 1
D
ow
nloaded from
 https://academ
ic.oup.com
/cercor/article-abstract/27/1/216/2737439 by U
niversity of N
ew
castle user on 24 January 2020
mRNA metabolism in dendrites. Proc Natl Acad Sci USA.
110:3125–3130.
Koehnke J, Katsamba PS, Ahlsen G, Bahna F, Vendome J, Honig B,
Shapiro L, Jin X. 2010. Splice form dependence of beta-neurexin/
neuroligin binding interactions. Neuron. 67:61–74.
Konopka G, Wexler E, Rosen E, Mukamel Z, Osborn GE, Chen L,
Lu D, Gao F, Gao K, Lowe JK, et al. 2012. Modeling the func-
tional genomics of autism using human neurons. Mol
Psychiatr. 17:202–214.
Kostovic´ I, Rakic P. 1990. Developmental history of the transient
subplate zone in the visual and somatosensory cortex of the
macaque monkey and human brain. J Comp Neurol. 297:
441–470.
Kostovic´ I, Sedmak G, Vukšic´ M, Judaš M. 2015. The relevance of
human fetal subplate zone for developmental neuropathol-
ogy of neuronal migration disorders and cortical dysplasia.
CNS Neurosci Therapeut. 21:74–82.
Kubota M, Miyata J, Sasamoto A, Sugihara G, Yoshida H,
Kawada R, Fujimoto S, Tanaka Y, Sawamoto N, Fukuyama
H, et al. 2013. Thalamocortical disconnection in the orbito-
frontal region associated with cortical thinning in schizo-
phrenia. JAMA Psychiatry. 70:12–21.
Kunwar AJ, Rickmann M, Backofen B, Browski SM, Rosenbusch J,
Schoning S, Fleischmann T, Krieglstein K, von Mollard GF.
2010. Proc Nat Acad Sci USA. 108:2575–2580.
Lathia JD, Patton B, Eckley DM, Magnus T, Mughal MR, Sasaki T,
Caldwell MA, Rao MS, Mattson MP, Ffrench-Constant C.
2007. Patterns of laminins and integrins in the embryonic
ventricular zone of the CNS. J Comp Neurol. 505:630–643.
Lindsay S, Xu Y, Lisgo S, Harkin LF, Copp A, Gerrelli D, Clowry GJ,
Talbot A, Wilson I, Coxhead J, et al. 2016. A unique resource
for global and individual gene expression studies during early
human brain development. Front Neuroanat. 10:86.
Love M, Anders S, Huber W. 2014. Moderated estimation of fold
change and dispersion for RNA-Seq data with DESeq2.
Genome Biol. 15:50.
Maness PF, Schachner M. 2007. Neural recognition molecules of
the immunoglobulin superfamily: signalling transducers of
axon guidance and neuronal migration. Nature Neurosci. 10:
19–26.
McFadden K, Minshew NJ. 2013. Evidence for dysregulation of
axonal growth and guidance in the etiology of ASD. Front
Human Neurosci. 7:671.
Missler M, Südhof TC. 1998. Neurexins: three genes and 1001
products. Trends Genet. 14:20–26.
Missler M, Zhang W, Rohlmann A, Kattenstroth G, Hammer RE,
Gottmann K, Südhof TC. 2003. Alpha-neurexins couple Ca2+
channels to synaptic vesicle exocytosis. Nature. 214:939–948.
Moore AR, Filipovic R, Mo Z, Rasband MN, Zecevic N, Antic SD.
2009. Electrical excitability of early neurons in the human
cerebral cortex during the second trimester of gestation.
Cereb Cortex. 19:1795–1805.
Morante-Oria J, Carleton A, Ortino B, Kremer EJ, Fairén A,
Lledo PM. 2003. Subpallial origin of a population of project-
ing pioneer neurons during corticogenesis. Proc Natl Acad
Sci USA. 100:12468–12473.
Miyata J, Hirao K, Namiki C, Fujiwara H, Shimizu M, Fukuyama
H, Sawamoto N, Hayashi T, Murai T. 2009. Reduced white
matter integrity correlated with cortico-subcortical gray
matter deficits in schizophrenia. Schizophr Res. 111:78–85.
Occhi G, Rampazzo A, Beffagna G, Danieli GA. 2002. Identifica-
tion and characterization of heart-specific splicing of
human neurexin 3 mRNA (NRXN3). Biochem Biophys Res
Commun. 298:151–155.
O’Connor VM, Shamotienko O, Grishin E, Betz H. 1993. On the
structure of the ‘synaptosecretosome’. Evidence for a
neurexin/synaptotagmin/syntaxin/Ca2+ channel complex.
FEBS Lett. 326:255–260.
O’Rahilly R, Müller F, Hutchins GM, Moore GW. 1987. Computer
ranking of the sequence of appearance of 73 features of the
brain and related structures in staged human embryos dur-
ing the sixth week of development. Am J Anat. 180:69–86.
Peñagarikano O, Abrahams BS, Herman EI, Winden KD,
Gdalyahu A, Dong H, Sonnenblick LI, Gruver R, Almajano J,
Bragin A, et al. 2011. Absence of CNTNAP2 leads to epilepsy,
neuronal migration abnormalities, and core autism-related
deficits. Cell. 147:235–246.
Petrenko AG, Ullrich B, Missler M, Krasnoperov V, Rosahl TW,
Südhof TC. 1996. Structure and evolution of neurexophilin.
J Neurosci. 16:4360–4369.
Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R,
Conroy J, Magalhaes TR, Correia C, Abrahams BS, et al. 2010.
Functional impact of global rare copy number variation in
autism spectrum disorders. Nature. 466:368–372.
Poliak S, Gollan L, Martinez R, Custer A, Einheber S, Salzer JL,
Trimmer JS, Shrager P, Peles E. 1999. Caspr2, a new member
of the neurexin superfamily, is localized at the juxtapara-
nodes of myelinated axons and associates with K+ chan-
nels. Neuron. 24:1037–1047.
Puschel AW, Betz H. 1995. Neurexins are differentially expressed
in the embryonic nervous system of mice. J Neurosci. 15:
2849–2856.
Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities
for comparing genomic features. Bioinformatics. 26:841–842.
Redies C, Hertel N, Hubner CA. 2012. Cadherins and neuro-
psychiatric disorders. Brain Res. 1470:130–144.
Reichelt AC, Rodgers RJ, Clapcote SJ. 2012. The role of neurexins
in schizophrenia and autistic spectrum disorder. Neuro-
pharmacol. 62:1519–1526.
Reissner C, Runkel F, Missler M. 2013. Neurexins. Genome Biol.
13:213.
Rowen L, Young J, Birditt B, Kaur A, Madan A, Philipps DL, Qin
S, Minx P, Wilson RK, Hood L, Graveley BR. 2002. Analysis of
the human neurexin genes: alternative splicing and the gen-
eration of protein diversity. Genomics. 14:587–597.
Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR,
Toulopoulou, Picchioni M, Vassos E, Ettinger U, Bramon E,
et al. 2009. Disruption of the neurexin 1 gene is associated
with schizophrenia. Hum Mol Genet. 18:988–996.
Schreiner D, Nguyen T-M, Russo G, Heber S, Patrignani A,
Ahrné E, Scheiffele P. 2014. Targeted combinatorial alterna-
tive splicing generates brain region-specific repertoires of
neurexins. Neuron. 84:386–298.
Schreiner D, Simicevic J, Ahrné E, Schmidt A, Scheiffele P. 2015.
Quantitative isoform-profiling of highly diversified recogni-
tion molecules. Elife. 18:e07794.
Scott-Van Zeeland AA, Abrahams BS, Alvarez-Retuerto AI,
Sonnenblick LI, Rudie JD, Ghahremani D, Mumford JA,
Poldrack RA, Dapretto M, Geschwind DH, et al. 2010. Altered
functional connectivity in frontal lobe circuits is associated
with variation in the autism risk gene CNTNAP2. Sci Transl
Med. 2:56RA80.
Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin
SE, Parod JM, Stephan DA, Morton DH. 2006. Recessive symp-
tomatic focal epilepsy and mutant contactin-associated pro-
tein-like 2. N Engl J Med. 354:1370–1377.
Südhof TC. 2001. alpha-latrotoxin and its receptors: neurexins
and CIRL/latrophilins. Ann Rev Neurosci. 24:933–962.
Neurexins 1–3 Each Have a Distinct Pattern of Expression Harkin et al. | 231
D
ow
nloaded from
 https://academ
ic.oup.com
/cercor/article-abstract/27/1/216/2737439 by U
niversity of N
ew
castle user on 24 January 2020
Südhof TC. 2008. Neuroligins and neurexins link synaptic func-
tion to cognitive disease. Nature. 455:903–911.
Sugita S, Saito F, Tang J, Satz J, Campbell K, Südhof TC. 2001. A
stoichiometric complex of neurexins and dystroglycan in
brain. J Cell Biol. 154:435–445.
Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J,
Liu XQ, Vincent JB, Skaug JL, Thompson AP, Senman L, et al.
2007. Mapping autism risk loci using genetic linkage and
chromosomal rearrangements. Nat Genet. 39:319–328.
Tabuchi K, Südhof TC. 2002. Structure and evolution of neurex-
in genes: insight into the mechanism of alternative splicing.
Genomics. 79(8):49–59.
Taverna E, Huttner WB. 2010. Neural progenitor nuclei IN
motion. Neuron. 67:906–914.
Traunmuller L, Bornmann C, Scheiffele P. 2014. Alternative spli-
cing coupled nonsense mediated decay generates neuronal
cell type specific expression of SLM proteins. J Neurosci . 34:
16755–16761.
Tsaneva-Atanasova K, Burgo A, Galli T, Holcman D. 2009.
Quantifying neurite growth mediated by interactions among
secretory vesicles, microtubules, and actin networks.
Biophys J. 96:840–857.
Ullrich B, Ushkaryov YA, Südhof TC. 1995. Cartography of neur-
exins: more than 1000 isoforms generated by alternative
splicing and expressed in distinct subsets of neurons.
Neuron. 14:497–507.
Ushkaryov YA, Hata Y, Ichtchenko K, Moomaw C, Afendis S,
Slaughter CA, Südhof TC. 1994. Conserved domain structure
of beta-neurexins. Unusual cleaved signal sequences in
receptor-like neuronal cell-surface proteins. J Biol Chem.
269:11987–11992.
Vaags AK, Lionel AC, Sato D, Goodenberger M, Stein QP, Curran
S, Ogilvie C, Ahn JW, Drmic I, Senman L, et al. 2012. Rare
deletions at the neurexin 3 locus in autism spectrum dis-
order. Am J Hum Genet. 90:133–141.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F. 2002. Accurate normalization of real-
time quantitative RT-PCR data by geometric averaging of
multiple internal control genes. Genome Biol. 3:7.
Viñas-Jornet M, Esteba-Castillo S, Gabau E, Ribas-Vidal N,
Baena N, San J, Ruiz A, Coll MD, Novell R, Guitart M. 2014. A
common cognitive, psychiatric, and dysmorphic phenotype
in carriers of NRXN1 deletion. Mol Genet Genomic Med. 2:
512–521.
Vuong CK, Black DL, Zheng S. 2016. The neurogenetics of alter-
native splicing. Nature Neurosci Rev. 17:265–281.
Wang TF, Ding CN, Wang GS, Luo SC, Lin YL, Ruan Y, Hevner R,
Rubenstein JL, Hsueh YP. 2004. Identification of Tbr-1/CASK
complex target genes in neurons. J Neurochem. 91:1483–1492.
Wei JL, Fu ZX, Fang M, Zhou QY, Zhao QN, Guo JB, Lu WD,
Wang H. 2014. High expression of CASK correlates with pro-
gression and poor prognosis of colorectal cancer. Tumour
Biol. 35:9185–9194.
Ye H, Liu J, Wu JY. 2010. Cell adhesion molecules and their
involvement in autism spectrum disorder. Neurosignals. 18:
62–71.
Zhang W, Rohlmann A, Sargsyan V, Aramuni G, Hammer RE,
Südhof TC, Missler M. 2005. Extracellular domains of alpha-
neurexins participate in regulating synaptic transmission by
selectively affecting N- and P/Q-type Ca2+ channels.
J Neurosci. 25:4330–4342.
Zhang Q, Wang J, Li A, Liu H, Zhang W, Cui X, Wang K. 2013.
Expression of neurexin and neuroligin in the enteric ner-
vous system and their down-regulated expression levels in
Hirschsprung disease. Mol Bio Rep. 40:2969–2975.
Zhao S, Fernald RD. 2005. Comprehensive algorithm for quanti-
tative real-time polymerase chain reaction. J Comput Biol.
12:1047–1064.
Zylbersztejn K, Galli T. 2011. Vesicular traffic in cell navigation.
FEBS J. 278:4497–4505.
232 | Cerebral Cortex, 2017, Vol. 27, No. 1
D
ow
nloaded from
 https://academ
ic.oup.com
/cercor/article-abstract/27/1/216/2737439 by U
niversity of N
ew
castle user on 24 January 2020
